Literature DB >> 8522463

Imipenem resistance in clinical isolates of Proteus mirabilis associated with alterations in penicillin-binding proteins.

C Neuwirth1, E Siébor, J M Duez, A Péchinot, A Kazmierczak.   

Abstract

Two strains of Proteus mirabilis, IpR1 and IpR2, resistant to both imipenem and mecillinam, but susceptible to other beta-lactams were isolated from blood cultures of patients who had been treated with imipenem. Strain IpR1 was isolated in the same sample as a P. mirabilis IpS1 which was susceptible to imipenem and mecillinam. Strains IpR1 and IpR2 did not produce a beta-lactamase and their outer membrane protein profiles were similar to those of IpS1 and P. mirabilis ATCC 29906. Electrophoretic profiles of penicillin-binding proteins (PBPs) showed a decrease in PBP 1A of strains IpR1 and IpR2 compared with IpS1 and ATCC 29906. Competition experiments revealed a decrease in affinity of PBP 2 for imipenem from strain IpR1. These findings suggest that imipenem resistance in P. mirabilis might result from altered PBPs, as reported for Acinetobacter baumanii and Pseudomonas aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8522463     DOI: 10.1093/jac/36.2.335

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  24 in total

1.  Evidence of in vivo transfer of a plasmid encoding the extended-spectrum beta-lactamase TEM-24 and other resistance factors among different members of the family Enterobacteriaceae.

Authors:  C Neuwirth; E Siebor; A Pechinot; J M Duez; M Pruneaux; F Garel; A Kazmierczak; R Labia
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

2.  Potential impact of the VITEK 2 system and the Advanced Expert System on the clinical laboratory of a university-based hospital.

Authors:  C C Sanders; M Peyret; E S Moland; S J Cavalieri; C Shubert; K S Thomson; J M Boeufgras; W E Sanders
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

3.  Carbapenem resistance in Escherichia coli associated with plasmid-determined CMY-4 beta-lactamase production and loss of an outer membrane protein.

Authors:  P D Stapleton; K P Shannon; G L French
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

4.  Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.

Authors:  Hervé Dupont; Olivier Gaillot; Anne-Sophie Goetgheluck; Claire Plassart; Jean-Philippe Emond; Marion Lecuru; Nicolas Gaillard; Sarah Derdouri; Baptiste Lemaire; Marion Girard de Courtilles; Vincent Cattoir; Hedi Mammeri
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

5.  Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities.

Authors:  Bartolomé Moyá; Alejandro Beceiro; Gabriel Cabot; Carlos Juan; Laura Zamorano; Sebastián Alberti; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2012-06-25       Impact factor: 5.191

6.  Carbapenem resistance in a clinical isolate of Citrobacter freundii.

Authors:  J L Mainardi; P Mugnier; A Coutrot; A Buu-Hoï; E Collatz; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

Review 7.  Recognizing and Overcoming Resistance to New Beta-Lactam/Beta-Lactamase Inhibitor Combinations.

Authors:  Stephanie Ho; Lynn Nguyen; Trang Trinh; Conan MacDougall
Journal:  Curr Infect Dis Rep       Date:  2019-09-09       Impact factor: 3.725

Review 8.  Carbapenems: past, present, and future.

Authors:  Krisztina M Papp-Wallace; Andrea Endimiani; Magdalena A Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

9.  Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection.

Authors:  Christopher Lucasti; Liviu Vasile; Dorel Sandesc; Donatas Venskutonis; Patrick McLeroth; Mallika Lala; Matthew L Rizk; Michelle L Brown; Maria C Losada; Alison Pedley; Nicholas A Kartsonis; Amanda Paschke
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

10.  In Vitro Activity of Imipenem-Relebactam against Clinical Isolates of Gram-Negative Bacilli Isolated in Hospital Laboratories in the United States as Part of the SMART 2016 Program.

Authors:  James A Karlowsky; Sibylle H Lob; Krystyna M Kazmierczak; Katherine Young; Mary R Motyl; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.